Andere Sprachen AEON Biopharma, Inc.

Aktien

A3EFKE

US00791X1000

AEON

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:05:12 10.06.2024			% 5 Tage	% 1. Jan.
1.57 ^USD	-6.55%		-3.96%	-78.12%

16.05.	AEON Biopharma, Inc. kündigt Änderungen in der Geschäftsführung an	CI
16.05.	AEON Biopharma, Inc. Deloitte, Inc. gibt Update der Phase-2-Doppelblindstudie von ABP-450 zur Behandlung von Migräne bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024	16.05.
AEON Biopharma, Inc. Announces Executive Changes	16.05.
AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine	16.05.
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
AEON Biopharma, Inc. Provides Update on Development Pipeline	09.05.
US Equity Markets Close Higher Friday Following Weak Jobs Report	03.05.
Sector Update: Health Care Stocks Mixed Late Afternoon	03.05.
Sector Update: Health Care	03.05.
Top Midday Decliners	03.05.
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	03.05.
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial	03.05.
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine	03.05.
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	12.04.
Sector Update: Health Care Stocks Slide Late Afternoon	01.04.
Sector Update: Health Care	01.04.
AEON Biopharma Shares Tumble on Wider Q4 Loss	01.04.
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.03.
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	19.03.
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AEON Biopharma, Inc.

Aktien

A3EFKE

US00791X1000

AEON

Andere Sprachen

Filter